165 related articles for article (PubMed ID: 9154963)
41. Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor.
Fuchs-Young R; Glasebrook AL; Short LL; Draper MW; Rippy MK; Cole HW; Magee DE; Termine JD; Bryant HU
Ann N Y Acad Sci; 1995 Jun; 761():355-60. PubMed ID: 7625735
[No Abstract] [Full Text] [Related]
42. Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia.
Evans GL; Bryant HU; Magee DE; Turner RT
Endocrinology; 1996 Oct; 137(10):4139-44. PubMed ID: 8828469
[TBL] [Abstract][Full Text] [Related]
43. An estrogen receptor basis for raloxifene action in bone.
Bryant HU; Glasebrook AL; Yang NN; Sato M
J Steroid Biochem Mol Biol; 1999; 69(1-6):37-44. PubMed ID: 10418979
[TBL] [Abstract][Full Text] [Related]
44. The selective estrogen receptor modulator, raloxifene: an overview of nonclinical pharmacology and reproductive and developmental testing.
Buelke-Sam J; Bryant HU; Francis PC
Reprod Toxicol; 1998; 12(3):217-21. PubMed ID: 9628546
[TBL] [Abstract][Full Text] [Related]
45. Characterization of selective estrogen receptor modulator (SERM) activity in two triarylethylene oxybutyric acids.
Rubin VN; Ruenitz PC; Boyd JL; Boudinot FD; Wiese TE
Biochem Pharmacol; 2002 Apr; 63(8):1517-25. PubMed ID: 11996894
[TBL] [Abstract][Full Text] [Related]
46. Raloxifene, a new selective estrogen receptor modulator.
Goldfrank D; Haytoglu T; Frishman WH; Mohammad Z
J Clin Pharmacol; 1999 Aug; 39(8):767-74. PubMed ID: 10434227
[TBL] [Abstract][Full Text] [Related]
47. Biological activities of a novel selective oestrogen receptor modulator derived from raloxifene (Y134).
Ning M; Zhou C; Weng J; Zhang S; Chen D; Yang C; Wang H; Ren J; Zhou L; Jin C; Wang MW
Br J Pharmacol; 2007 Jan; 150(1):19-28. PubMed ID: 17115070
[TBL] [Abstract][Full Text] [Related]
48. A new selective estrogen receptor modulator with potent uterine antagonist activity, agonist activity in bone, and minimal ovarian stimulation.
Geiser AG; Hummel CW; Draper MW; Henck JW; Cohen IR; Rudmann DG; Donnelly KB; Adrian MD; Shepherd TA; Wallace OB; McCann DJ; Oldham SW; Bryant HU; Sato M; Dodge JA
Endocrinology; 2005 Oct; 146(10):4524-35. PubMed ID: 16002528
[TBL] [Abstract][Full Text] [Related]
49. Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene.
Overk CR; Peng KW; Asghodom RT; Kastrati I; Lantvit DD; Qin Z; Frasor J; Bolton JL; Thatcher GR
ChemMedChem; 2007 Oct; 2(10):1520-6. PubMed ID: 17654759
[TBL] [Abstract][Full Text] [Related]
50. In vitro estrogenic actions in rat and human cells of hydroxylated derivatives of D16726 (zindoxifene), an agent with known antimammary cancer activity in vivo.
Robinson SP; Koch R; Jordan VC
Cancer Res; 1988 Feb; 48(4):784-7. PubMed ID: 3338076
[TBL] [Abstract][Full Text] [Related]
51. Design, synthesis and bioevaluation of novel candidate selective estrogen receptor modulators.
Yadav Y; Maclean ED; Bhattacharyya A; Parmar VS; Balzarini J; Barden CJ; Too CK; Jha A
Eur J Med Chem; 2011 Sep; 46(9):3858-66. PubMed ID: 21680064
[TBL] [Abstract][Full Text] [Related]
52. Flexible estrogen receptor modulators: design, synthesis, and antagonistic effects in human MCF-7 breast cancer cells.
Meegan MJ; Hughes RB; Lloyd DG; Williams DC; Zisterer DM
J Med Chem; 2001 Mar; 44(7):1072-84. PubMed ID: 11297454
[TBL] [Abstract][Full Text] [Related]
53. Ethyl side-chain modifications in novel flexible antiestrogens--design, synthesis and biological efficacy in assay against the MCF-7 breast tumor cell line.
Meegan MJ; Hughes RB; Lloyd DG; Williams DC; Zisterer DM
Anticancer Drug Des; 2001 Feb; 16(1):57-69. PubMed ID: 11762645
[TBL] [Abstract][Full Text] [Related]
54. Design, synthesis and bioevaluation of novel 6-(4-Hydroxypiperidino)naphthalen-2-ol-based potential Selective Estrogen Receptor Modulators for breast cancer.
Jha A; Yadav Y; Naidu AB; Rao VK; Kumar A; Parmar VS; MacDonald WJ; Too CK; Balzarini J; Barden CJ; Cameron TS
Eur J Med Chem; 2015 Mar; 92():103-14. PubMed ID: 25544690
[TBL] [Abstract][Full Text] [Related]
55. Raloxifene acts as an estrogen agonist on the rabbit growth plate.
Nilsson O; Falk J; Ritzén EM; Baron J; Sävendahl L
Endocrinology; 2003 Apr; 144(4):1481-5. PubMed ID: 12639932
[TBL] [Abstract][Full Text] [Related]
56. In vitro evaluation, biodistribution in rats of radiolabeled raloxifene.
Bayrak E; Lambrecht FY; Durkan K; Yilmaz O
Appl Radiat Isot; 2010 Jan; 68(1):33-6. PubMed ID: 19819155
[TBL] [Abstract][Full Text] [Related]
57. Synthesis and biological activity of trans-2,3-dihydroraloxifene.
Schmid CR; Glasebrook AL; Misner JW; Stephenson GA
Bioorg Med Chem Lett; 1999 Apr; 9(8):1137-40. PubMed ID: 10328300
[TBL] [Abstract][Full Text] [Related]
58. Selective estrogen receptor modulators (SERMs).
Grese TA; Dodge JA
Curr Pharm Des; 1998 Feb; 4(1):71-92. PubMed ID: 10197034
[TBL] [Abstract][Full Text] [Related]
59. 1-(2-[4-[6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiol-3-ylcarbonyl]phenoxy]ethyl)piperidinium chloride.
Vega D; Fernández D; Ellena JA
Acta Crystallogr C; 2001 Sep; 57(Pt 9):1092-4. PubMed ID: 11588381
[TBL] [Abstract][Full Text] [Related]
60. Anti-implantation effect of 2-[piperidinoethoxyphenyl]-3-[4-hydroxyphenyl]-2H-benzo(b)pyran, a potent antiestrogenic agent in rats.
Kharkwal G; Fatima I; Kitchlu S; Singh B; Hajela K; Dwivedi A
Fertil Steril; 2011 Mar; 95(4):1322-7. PubMed ID: 20674906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
